"10.1371_journal.pone.0125214","plos one","2015-06-24T00:00:00Z","Beat Müllhaupt; Philip Bruggmann; Florian Bihl; Sarah Blach; Daniel Lavanchy; Homie Razavi; David Semela; Francesco Negro","Swiss HPB (Hepato-Pancreato-Biliary) Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland; Arud Centres for Addiction Medicine, Zürich, Switzerland; Gastroenterology Department, Ospedale Cantonale, Bellinzona, Switzerland; Center for Disease Analysis (CDA), Louisville, Colorado, United States of America; Consultant, Ruelle des Chataigniers 1, CH-1026 Denges VD, Switzerland; Division of Gastroenterology & Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland","Conceived and designed the experiments: BM PB FB SB DL HR DS FN. Performed the experiments: BM PB FB SB DL HR DS FN. Analyzed the data: BM PB FB SB DL HR DS FN. Contributed reagents/materials/analysis tools: BM PB FB SB DL HR DS FN. Wrote the paper: BM PB FB SB DL HR DS FN.","Beat Müllhaupt has served as an advisory board member for Roche, MSD, Janssen Therapeutics, AbbVie, Boehringer Ingelheim, Gilead and BMS; as a consultant for Gilead and AbbVie; and has received research grants from Roche and Gilead. Philip Bruggmann has served as advisor and speaker for, and has received project and research grants from Roche, MSD, Janssen, AbbVie, Gilead, Viif and BMS. Sarah Blach and Homie Razavi are employees of the Center for Disease Analysis (CDA), Louisville, Colorado, USA. David Semela has served as a consultant for Gilead, an advisor for Roche, MSD, Gilead, Novartis, Janssen and Boehringer Ingelheim and has received an unrestricted research grant from Roche. Francesco Negro has served as advisor for MSD, Gilead, Novartis, Bristol Myers Squibb, AbbVie and Janssen and has received unrestricted research grants from Roche and Gilead. Florian Bihl and Daniel Lavanchy have no conflicts of interest to declare. As part of this project, none of the authors were part of any activities related to patents, product development or marketed products. The funding of this project by Gilead does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2015","06","Beat Müllhaupt","BM",8,TRUE,8,8,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
